Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Pet Cancer Therapeutics Market

Pet Cancer Therapeutics Market Share

Report ID: GMI2017
Published Date: Dec 2024
Report Format: PDF

Download Free Sample

Pet Cancer Therapeutics Market Share

The market is highly competitive, with the presence of key players. The companies are striving focus on expanding their product portfolios through innovations in chemotherapy, immunotherapy, and targeted treatments. In addition, strategic partnerships, acquisitions, and investments in research and development further strengthens the market positions. Furthermore, the growing demand for advanced pet cancer treatments has led to increased competition, driving innovation and the introduction of novel therapeutics to meet diverse consumer needs.

Pet Cancer Therapeutics Market Companies

Few of the prominent players operating in the pet cancer therapeutics industry include:

AB Science
Boehringer Ingelheim International
CureLab Oncology
Dechra Pharmaceuticals
Elanco Animal Health
ELIAS Animal Health
NovaVive
Qbiotics
Pfizer
Torigen
Vibrac
Vivesto
Zoetis

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The pet cancer therapeutics industry was valued at USD 477.1 million in 2024 and is estimated to grow at a 9.7% CAGR from 2025 to 2034, driven by the increasing trend of pet humanization.

The dog segment dominated the market with a valuation of USD 402 million in 2024 due to the higher incidence of cancer in dogs compared to other pets.

The U.S. held a significant position in the North American pet cancer therapeutics market in 2024 and is projected to dominate with a 9.3% CAGR throughout the forecast period, supported by advanced veterinary healthcare infrastructure and high pet ownership rates.

Key players in the industry include AB Science, Boehringer Ingelheim International, CureLab Oncology, Dechra Pharmaceuticals, Elanco Animal Health, ELIAS Animal Health, NovaVive, Qbiotics, Pfizer, Torigen, and Vibrac.